As per the deal, PeptiDream will use its Peptide Discovery Platform System (PDPS) technology for generating macrocyclic/constrained peptides against several targets of interest selected by Teijin. Teijin will
Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone is indicated to treat adult patients with multiple myeloma who have received at least one prior therapy. BLINCYTO (blinatumomab) can
Entresto, earlier known as LCZ696, will be available to treat adult patients with symptomatic chronic heart failure and reduced ejection fraction (HfrEF) after final approval from the European
Praluent, which is being developed by Sanofi and Regeneron Pharmaceuticals, will be available in both a 75 mg and 150 mg dose for self-administration every two weeks. It
The Accurin drug candidate is intended at treating solid tumors. The actively targeted Accurin is designed to impart cellular targeting capability. Pfizer’s decision results in a $2.5m payment
Mylan, Amneal Pharmaceuticals, Roxane Laboratories, Actavis and Sandoz had filed abbreviated new drug applications (ANDAs) to market generic versions of Vyvanse. Following the drug makers’ plan to create
The institute granted the funding under its CIRM 2.0 program, which is designed to speed up the development of stem cell-based treatments for people with unmet medical requirements.
In its final draft guidance, the regulator recommended Zydelig for patients whose leukaemia has come back less than two years following earlier treatment. Earlier this year, NICE asked
The European Medicines Agency’s Committee for Medicinal Products for Human Use gives its recommendations for marketing authorization to drugs to the European Commission (EC). The commission is expected
Keryx carried out a phase 2, non-dialysis study and a 58-week, phase 3 registration trial on about 1900 patients. The company said in the phase 3 trial, ferric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.